Therapeutic delivery最新文献_第6页

Antitumor activity of silver (Ag) complexes in colorectal cancer cells by oxidative stress and apoptosis induction. 银（Ag）复合物在氧化应激和凋亡诱导下对结直肠癌细胞的抗肿瘤活性。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-05-18 DOI: 10.1080/20415990.2026.2668266

Sin-Yeang Teow, Hui Xuan Lim, Ying Yin, Hongyuan Miao, Jing Yu Lim, Raahilah Zahir Essa, Jack Bee Chook, Yee Seng Tan, Chien Ing Yeo

{"title":"Antitumor activity of silver (Ag) complexes in colorectal cancer cells by oxidative stress and apoptosis induction.","authors":"Sin-Yeang Teow, Hui Xuan Lim, Ying Yin, Hongyuan Miao, Jing Yu Lim, Raahilah Zahir Essa, Jack Bee Chook, Yee Seng Tan, Chien Ing Yeo","doi":"10.1080/20415990.2026.2668266","DOIUrl":"10.1080/20415990.2026.2668266","url":null,"abstract":"Aims: Metal-based drugs, such as the platinum-derived compounds cisplatin and oxaliplatin, are routinely used in cancer therapy. Currently, among these, only oxaliplatin has demonstrated significant efficacy in colorectal cancer (CRC). This urges the necessity of developing more effective anticancer agents.Materials and methods: Two bis(phosphine)silver(I) complexes with a general formula of (Ph3P)2AgCl{ROC(=S)N(H)Ph, with R = Me (Ag1) and Et (Ag2) were prepared to evaluate their anticancer effects and underlying mechanisms of action in CRC cells.Results and conclusions: The precursor ((Ph3P)2AgCl; Ag) and its complexes bearing a thiocarbamide moiety effectively inhibited the proliferation of HCT116 and HT-29 CRC cells. Notably, Ag1 and Ag2 demonstrated potent activity in disintegrating 3D spheroids, surpassing the efficacy of both the Ag precursor and cisplatin. Mechanistic investigations revealed that Ag and Ag1 induced the production of reactive oxygen species (ROS) and superoxide in CRC cells, while all Ag complexes including the precursor triggered cell apoptosis. The collective findings indicate that the synthesized Ag complexes potently kill CRC cells through oxidative stress induction and programmed cell death.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"313-323"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-carrier molecular incompatibility as a hidden determinant of failure in cancer nanomedicine: investigation of possible solutions. 药物载体分子不相容性是癌症纳米医学失败的潜在决定因素：可能解决方案的研究。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-04-21 DOI: 10.1080/20415990.2026.2662808

Dilpreet Singh, Sankha Bhattacharya

{"title":"Drug-carrier molecular incompatibility as a hidden determinant of failure in cancer nanomedicine: investigation of possible solutions.","authors":"Dilpreet Singh, Sankha Bhattacharya","doi":"10.1080/20415990.2026.2662808","DOIUrl":"10.1080/20415990.2026.2662808","url":null,"abstract":"Despite major advances, the clinical translation of cancer nanomedicine remains limited, with only a small proportion of formulations reaching regulatory approval. Although tumor heterogeneity, biological barriers, and patient-to-patient variability are commonly blamed, growing evidence suggests that drug-carrier molecular incompatibility is a fundamental and underrecognized cause of translational failure. In this review, molecular compatibility is defined as the thermodynamically and kinetically stable association between a therapeutic agent and its nanocarrier, governed by hydrophobic partitioning, electrostatic interactions, hydrogen bonding, miscibility, and crystallization behavior. By contrast, incompatibility refers to physicochemical mismatches that destabilize drug loading, trigger premature release, induce structural rearrangement, or alter biodistribution. Common manifestations include burst release, aggregation, chemical degradation, and loss of colloidal stability, all of which can reduce tumor accumulation, increase systemic toxicity, and weaken therapeutic efficacy. Evidence from both failed and clinically successful nanomedicines indicates that molecular compatibility, rather than carrier complexity alone, is a critical determinant of translational success. Experimental, spectroscopic, and computational methods for compatibility assessment are reviewed, together with rational design strategies including carrier selection, drug modification, surface engineering, and smart delivery systems. This review highlights compatibility as a central design and regulatory consideration in cancer nanomedicine.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"337-355"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Target-specific daunorubicin nanoplatform based on anti-CD22-ScFv decorated β-cyclodextrin metal organic frameworks. 基于抗cd22 - scfv修饰β-环糊精金属有机框架的靶向柔红霉素纳米平台。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-05-25 DOI: 10.1080/20415990.2026.2668852

Alireza Khabiri, Banafsheh Rastegari, Gholamreza Rafiei Dehbidi, Amir Savardashtaki, Mohammad Ali Takhshid

{"title":"Target-specific daunorubicin nanoplatform based on anti-CD22-ScFv decorated β-cyclodextrin metal organic frameworks.","authors":"Alireza Khabiri, Banafsheh Rastegari, Gholamreza Rafiei Dehbidi, Amir Savardashtaki, Mohammad Ali Takhshid","doi":"10.1080/20415990.2026.2668852","DOIUrl":"10.1080/20415990.2026.2668852","url":null,"abstract":"Aims: This study aimed to develop a targeted drug delivery system based on anti-CD22 single-chain variable fragment (ScFv) conjugated to β-cyclodextrin (β-CD) Bio-MOFs for the selective delivery of daunorubicin (DNR) to CD22-positive B-cell tumor cells.Materials and methods: The anti-CD22-ScFv gene was designed using the variable heavy (VH) and light (VL) chain regions of the human RFB4 antibody and cloned into the pET28a vector, followed by expression in E. coli BL21 (DE3). The recombinant protein was purified by affinity chromatography and confirmed by SDS-PAGE. Anti-CD22-ScFv-β-CD Bio-MOFs were synthesized using glutaraldehyde and L-lysine as crosslinkers and subsequently loaded with DNR. The formation of the nanostructure was verified by ATR-FTIR spectroscopy and zeta potential analysis. Drug uptake and cytotoxic effects were evaluated in CD22-positive Raji cells and CD22-negative Jurkat cells using fluorescence microscopy, flow cytometry, and the MTT assay.Results: Successful expression and purification of anti-CD22-ScFv were confirmed by SDS-PAGE. Characterization analyses verified the formation of anti-CD22-ScFv-β-CD-DNR Bio-MOFs. The targeted system facilitated efficient uptake of DNR in CD22-positive Raji cells and induced significant dose-dependent cytotoxicity. In contrast, minimal effects were observed in CD22-negative Jurkat cells.Conclusions: Anti-CD22-ScFv-β-CD-DNR Bio-MOFs demonstrate effective and selective delivery of DNR to CD22-expressing cells and may represent a promising targeted therapeutic approach for B-cell malignancies.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"17 4","pages":"325-335"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Translational nanomedicine strategies for selective senescent cell clearance in aging and age-related diseases: a critical review. 在衰老和年龄相关疾病中选择性清除衰老细胞的转化纳米医学策略：一个重要的回顾。

IF 3.4

Therapeutic delivery Pub Date : 2026-04-01 Epub Date: 2026-05-05 DOI: 10.1080/20415990.2026.2668850

Dilpreet Singh, Sankha Bhattacharya

{"title":"Translational nanomedicine strategies for selective senescent cell clearance in aging and age-related diseases: a critical review.","authors":"Dilpreet Singh, Sankha Bhattacharya","doi":"10.1080/20415990.2026.2668850","DOIUrl":"10.1080/20415990.2026.2668850","url":null,"abstract":"Aging is driven by progressive cellular damage, dysfunction, and senescence, a therapeutically actionable contributor to chronic inflammation, tissue degeneration, and age-related disease. However, senolytic and senomorphic translation remains constrained by senescent-cell heterogeneity, narrow therapeutic windows, inconsistent exposure, limited tissue penetration, uncertain nanoparticle accumulation in poorly perfused aged organs, and the absence of definitive clinical efficacy. Nanomedicine should therefore be viewed not as generic drug packaging, but as a strategy to improve the senolytic index through controlled exposure, multi-step selectivity, intracellular delivery, and context-responsive release. This review critically evaluates lipid-based, polymeric, hybrid, and biomimetic nanoplatforms by asking whether they improve target engagement, functional recovery, and safety over free drugs, rather than merely increasing encapsulation efficiency or in vitro cytotoxicity. Emphasis is placed on assay-aware interpretation of quantitative claims, limitations of single-marker targeting, variability of EPR-like behavior in aging tissues, manufacturability, and regulatory readiness. Overall, nanomedicine-based senotherapy is highly promising but not yet clinically de-risked; meaningful progress will require disciplined biology-to-design integration, human-tissue validation, and rigorous benchmarking against clinically relevant outcomes.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"357-376"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-action depot formulation of hyaluronic acid/poloxamer in-situ gel enclosing lavender oil-based syringic acid nanoemulsion for enhanced intra-articular treatment of osteoarthritis. 透明质酸/波洛沙姆原位凝胶包覆薰衣草油基丁香酸纳米乳的双作用储存配方，用于增强骨关节炎的关节内治疗。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-04-08 DOI: 10.1080/20415990.2026.2653442

Noor Assalem, Hend Abd-Allah, Enas Elmowafy

{"title":"Dual-action depot formulation of hyaluronic acid/poloxamer in-situ gel enclosing lavender oil-based syringic acid nanoemulsion for enhanced intra-articular treatment of osteoarthritis.","authors":"Noor Assalem, Hend Abd-Allah, Enas Elmowafy","doi":"10.1080/20415990.2026.2653442","DOIUrl":"10.1080/20415990.2026.2653442","url":null,"abstract":"Aim: Osteoarthritis (OA) is a degenerative disorder affecting the joints and is portrayed by chronic pain and inflammation, impacting quality of life. Conventional treatments show limited efficacy due to inadequate drug delivery and suboptimal retention. The unique anti-inflammatory effects of syringic acid (SA) can be potentiated with the incorporation of lavender oil in a nanoemulsion for intra-articular delivery.Methods: Integrating a novel hyaluronic acid/poloxamer 407/poloxamer 188 (HA/P407/P188) in situ gel with SA-loaded lavender oil-based nanoemulsion was attempted. Colloidal features and suitability of the corresponding in situ gel for intra-articular delivery were demonstrated. In-vivo therapeutic efficacy on knee osteoarthritis induction model was also investigated.Results: The proposed nanoemulsion was designed with a droplet size of 214.5 ± 19.54 nm and a polydispersity index of 0.387 ± 0.060. HA/P407/P188 in situ gel further augments therapeutic outcomes for intra-articular administration by prolonging SA release approaching 6 days and offering appropriate sol-gel transition temperature and rheological patterns. In-vivo anti-arthritic activity was confirmed with a more reduced joint inflammation and downregulation of pro-inflammatory cytokine levels in knee joints compared to SA suspension.Conclusions: This study highlights the potential of the nanoemulsion in a HA/P407/P188 in-situ gel as a promising strategy for intra-articular OA therapy, with an enhanced sustained therapeutic efficacy.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"171-184"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aloe-emodin microemulsion gel for diabetic wounds: optimizing surfactant-polymer synergy for effective wound management. 芦荟-大黄素微乳凝胶用于糖尿病伤口：优化表面活性剂-聚合物协同有效的伤口管理。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-04-01 DOI: 10.1080/20415990.2026.2653453

Pankaj Popli, Sakshi Gaur, Sushma Devi, Srikanth Basety, Teenu Sharma, Thakur Gurjeet Singh, Rajan Swami

{"title":"Aloe-emodin microemulsion gel for diabetic wounds: optimizing surfactant-polymer synergy for effective wound management.","authors":"Pankaj Popli, Sakshi Gaur, Sushma Devi, Srikanth Basety, Teenu Sharma, Thakur Gurjeet Singh, Rajan Swami","doi":"10.1080/20415990.2026.2653453","DOIUrl":"10.1080/20415990.2026.2653453","url":null,"abstract":"Aim: The present study aimed to develop and optimize an Aloe-emodin-loaded microemulsion gel (AMEG) to improve topical delivery, bioavailability, and therapeutic efficacy for diabetic wound healing.Materials and methods: AMEG was formulated using a D-optimal mixture design, employing Capryol 90 as the oil phase, Labrasol and Tween 80 as surfactants, and Transcutol P as the co-surfactant. The optimized microemulsion was incorporated into a konjac glucomannan (KGM) gel matrix to enhance skin adherence and wound-healing potential. The formulation was characterized for droplet size, clarity, in vitro drug release, and ex vivo skin permeation. In vivo wound-healing efficacy was evaluated in diabetic rat models, along with biochemical and histopathological assessments.Results: The optimized AMEG exhibited a nanoscale droplet size of ~27.17 ± 2.65 nm with excellent clarity and stability. Sustained in vitro drug release (~45.8 ± 1.66%) and enhanced transdermal penetration (~39.5 ± 1.96%) were observed. In vivo studies demonstrated significantly accelerated wound closure, modulation of inflammatory and oxidative stress markers, and improved tissue regeneration. Histopathological evaluation confirmed complete re-epithelialization and well-organized collagen deposition.Conclusion: AMEG effectively overcomes the solubility and bioavailability limitations of Aloe-emodin, offering a promising topical therapeutic strategy for diabetic wound management through enhanced penetration, controlled release, and synergistic healing effects.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"203-216"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer. 皮下atezolizumab用于治疗非小细胞肺癌。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-04-07 DOI: 10.1080/20415990.2026.2655547

Jaime González-Montero, Carlos I Rojas, Mauricio Burotto

{"title":"Subcutaneous atezolizumab for the treatment of non-small cell lung cancer.","authors":"Jaime González-Montero, Carlos I Rojas, Mauricio Burotto","doi":"10.1080/20415990.2026.2655547","DOIUrl":"10.1080/20415990.2026.2655547","url":null,"abstract":"Subcutaneous atezolizumab (with rHuPH20) streamlines anti-PD-L1 delivery while preserving the intravenous (IV) formulation's performance. This review integrates pharmacokinetic, clinical, safety, patient-reported, and operational data from IMscin001 and related studies in NSCLC. A fixed 1,875-mg SC dose every 3 weeks provides bioavailability and steady-state exposure non-inferior to IV, meeting prespecified PK margins and maintaining target engagement. Across phase I-III trials in previously treated patients, objective response, progression-free survival, and overall survival are comparable between routes, with no new safety liabilities. Immune-related adverse events occur at expected rates and grades; the principal route-specific signal is infrequent, mild injection-site reactions. Patient-reported outcomes and preference consistently favor SC dosing due to markedly reduced chair time (~7-minute injection), lower treatment burden, and greater convenience. Time-and-motion analyses indicate meaningful capacity gains, particularly in maintenance settings and resource-constrained clinics. Implementation requires standard immunotoxicity monitoring, nursing competency for large-volume SC administration, and strict route verification. Key gaps include real-world effectiveness and pharmacovigilance at scale, determinants of inter-individual SC bioavailability, optimal injection technique/site, and integration with perioperative or chemotherapy combinations. Overall, SC atezolizumab offers a clinically robust, patient-centered alternative to IV therapy.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"249-258"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study. 脂质体-百里醌共包封增强妥布霉素和阿米卡星活性：抗菌、抗生物膜和细胞相容性研究。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-04-10 DOI: 10.1080/20415990.2026.2653455

Raghad R Alzahrani, Manal M Alkhulaifi, Abdulkareem M Albekairy, Bahauddeen M Alrfaei, Rizwan Ali, Salleh N Ehaideb, Mohammed A Assiri, Alaa Eldeen B Yassin, Majed A Halwani

{"title":"Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study.","authors":"Raghad R Alzahrani, Manal M Alkhulaifi, Abdulkareem M Albekairy, Bahauddeen M Alrfaei, Rizwan Ali, Salleh N Ehaideb, Mohammed A Assiri, Alaa Eldeen B Yassin, Majed A Halwani","doi":"10.1080/20415990.2026.2653455","DOIUrl":"10.1080/20415990.2026.2653455","url":null,"abstract":"Background and aim: Aminoglycoside antibiotics (AGAs) are vital but are faced with limited uptake, resistance, and nephrotoxicity. Thymoquinone (THQ) from Nigella sativa has antibacterial and cytoprotective effects but is unstable, posing challenges for formulation. This study co-encapsulated amikacin (AMK) and tobramycin (TOB) with THQ in liposomes to improve antimicrobial activity and renal cytocompatibility.Methods: Liposomes (Lipo-AMK-THQ and Lipo-TOB-THQ) were prepared and characterized using dynamic light scattering, zeta potential, encapsulation efficiency, Fourier transform infrared spectroscopy, and transmission electron microscopy. Antimicrobial efficacy was evaluated using minimum inhibitory or bactericidal concentrations (MIC-MBC), time-kill, and biofilm inhibition assays. Cytocompatibility was assessed in HK-2 and HEK293T cells.Results: Formulations exhibited nanoscale size (around 100 nm), low polydispersity (0.1-0.2), and zeta potential around -60 mV. Sustained antibiotic release over 24 h was observed. MIC values were reduced compared to free antibiotics, particularly against resistant MRSA and E. coli isolates (by up to 31-500-fold). Enhanced biofilm inhibition was observed (up to 90-98%) relative to free drugs (38-41%). Cell viability remained at 63-100% (HK-2) and 84-100% (HEK293T).Conclusion: Co-encapsulation of selected AGAs with THQ in liposomes improved antibacterial and antibiofilm activity while maintaining cytocompatibility, supporting further in vivo evaluation to establish the therapeutic potential and safety.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"217-231"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147646429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Industry update: the latest developments in the field of therapeutic delivery, December 2025. 行业更新：治疗递送领域的最新进展，2025年12月。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-03-13 DOI: 10.1080/20415990.2026.2642514

Peter Timmins

引用次数: 0

Harnessing 5-fluorouracil-loaded chitosan nanoparticles for targeted colon cancer therapy. 利用负载5-氟尿嘧啶的壳聚糖纳米颗粒靶向结肠癌治疗。

IF 3.4

Therapeutic delivery Pub Date : 2026-03-01 Epub Date: 2026-04-08 DOI: 10.1080/20415990.2026.2653447

Arghya Paria, Ekta Rawat, Sachin Sharma, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Sonam M Gandhi, Devesh U Kapoor

{"title":"Harnessing 5-fluorouracil-loaded chitosan nanoparticles for targeted colon cancer therapy.","authors":"Arghya Paria, Ekta Rawat, Sachin Sharma, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Sonam M Gandhi, Devesh U Kapoor","doi":"10.1080/20415990.2026.2653447","DOIUrl":"10.1080/20415990.2026.2653447","url":null,"abstract":"Colon cancer remains a significant global health burden, and although 5-fluorouracil (5-FU) is a cornerstone chemotherapeutic agent, its clinical utility is constrained by systemic toxicity and poor tumor selectivity. This review highlights recent advances in chitosan-based nanoparticles as targeted delivery systems for 5-FU in colon cancer therapy. Chitosan, a biocompatible and biodegradable polymer, offers advantages such as mucoadhesion and pH sensitivity, making it well-suited for colon-specific drug delivery. The review covers formulation strategies, physicochemical characterization, and in vitro/in vivo performance of 5-FU-loaded chitosan nanoparticles. Emphasis is placed on active targeting approaches, including ligand functionalization (e.g., folate and hyaluronic acid) to enhance receptor-mediated uptake in cancer cells. Additionally, the pH-responsive behavior of chitosan systems is discussed as a mechanism for controlled drug release within the acidic tumor microenvironment. Preclinical evidence indicates that chitosan nanoparticles improve the therapeutic index of 5-FU by enhancing tumor accumulation and minimizing off-target toxicity compared to the free drug. Overall, this nanocarrier system represents a promising strategy for safer and more effective colon cancer treatment. Literature was systematically sourced from PubMed, Scopus, Web of Science, and Google Scholar (2000-June 2025).","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"233-248"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0